MicroIslet strengthens islet cell transplant position:
This article was originally published in Clinica
Executive Summary
MicroIslet says that its protective intellectual property portfolio in the field of islet cell transplantation has received a boost. The statement comes after its processes for culturing and transplanting functional and viable islet cells - the major insulin-secreting cells - into people with insulin-dependent (type 1) diabetes mellitus was awarded a US patent. The patent is licensed exclusively to the San Diego, California company under an agreement with Duke University in Durham, North Carolina.